AstraZeneca (AZN) Q4 results:
Revenues: $6,664M (+3.8%); Product Sales: $6,250M (+8.4%); Collaboration Revenue: $414M (-36.2%).
Key product sales: Tagrisso: $884M (+49%);
Lynparza: $351M (+68%); Symbicort: $712M (+12%); Nexium: $353M (-10%);
Brilinta: $428M (+14%); Farxiga: $419M (+6%); Pulmicort: $413M (+6%);
Crestor: $296M (-4%); Imfinzi: $424M (+62%); Faslodex: $166M (-39%).
Net Income: $313M (-69.7%); EPS: $0.24 (-70.7%); non-GAAP EPS: $0.89; CF Ops: $4,861M (+26.9%).
2020 Guidance: Total revenue:
growth increase by a high single-digit to a low double-digit percentage;
Core EPS: to increase by a mid- to high-teens percentage.
Shares are down 2% premarket.
Previously: AstraZeneca EPS beats by $0.33, misses on revenue (Feb. 14)
https://seekingalpha.com/news/3542169-astrazeneca-slips-2-on-q4-results
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.